191 related articles for article (PubMed ID: 36322002)
1. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
3. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
4. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
7. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
10. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
11.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
12. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
[TBL] [Abstract][Full Text] [Related]
13. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
[TBL] [Abstract][Full Text] [Related]
15. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
17. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
18. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
19. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG; Camolotto SA; Boespflug AM; Guillen KP; Foth M; Truong A; Schuman SS; Shea JE; Seipp MT; Yap JT; Burrell LD; Lum DH; Whisenant JR; Gilcrease GW; Cavalieri CC; Rehbein KM; Cutler SL; Affolter KE; Welm AL; Welm BE; Scaife CL; Snyder EL; McMahon M
Nat Med; 2019 Apr; 25(4):620-627. PubMed ID: 30833748
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw J; Taylor KR; Bishop R; Valenti M; De Haven Brandon A; Gowan S; Eccles SA; Ruddle RR; Johnson LD; Raynaud FI; Selfe JL; Thway K; Pietsch T; Pearson AD; Shipley J
Clin Cancer Res; 2013 Nov; 19(21):5940-51. PubMed ID: 23918606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
